In search of the optimal management strategy for non ‐alcoholic fatty liver disease in type 2 diabetes

AbstractNon ‐alcoholic fatty liver disease (NAFLD) is present in over two‐thirds of individuals with type 2 diabetes. Diabetes increases the risk of NAFLD progression, especially the development of non‐alcoholic steatohepatitis (NASH), advanced fibrosis (AF; defined as fibrosis stage ≥3), and hepatocell ular carcinoma (HCC) (1). On the other hand, NAFLD also puts patients at a higher risk of cardiovascular diseases (CVD) (2). Driven by the rising prevalence of both obesity and type 2 diabetes, and increasing life‐expectancy of patients with type 2 diabetes consequent to the improved standard of c are, it is envisioned that NAFLD will soon become a major diabetic complication.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: JDI UPDATES Source Type: research